SAN DIEGO, Sept. 23, 2019 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies, will
participate in the 2019 Cantor Global Healthcare Conference in
New York, NY. Dr.
Helen Torley, president and chief
executive officer, will represent the company in a question and
answer session on Thursday, October 3
at 3:35 p.m. ET / 12:35 p.m. PT.
A live webcast of the presentation can be accessed through the
"Investors" section of www.halozyme.com, and a recording will be
made available for 90 days following each event. To access a live
webcast, please visit Halozyme's website approximately 15 minutes
prior to the presentation to register and download any necessary
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug
pegvorhyaluronidase alfa (PEGPH20), applies a unique approach to
targeting solid tumors, allowing increased access of
co-administered cancer drug therapies to the tumor in animal
models. PEGPH20 is currently in development for the treatment of
several cancers and has the potential to be used in combination
with different types of cancer therapies. In addition to its
proprietary product portfolio, Halozyme has established
value-driving partnerships with leading pharmaceutical and
biotechnology companies, including Roche, Baxalta, Pfizer, Janssen,
AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx, for its
ENHANZE® drug delivery technology. Halozyme is
headquartered in San Diego. For
more information visit www.halozyme.com.
Vice President, Investor Relations and Corporate Communications
View original content to download
SOURCE Halozyme Therapeutics, Inc.